GlaxoSmithKline PLC (GSK) has recalled more than 394,200 bottles of a drug used in the treatment for high-blood pressure due to the potential for tablet mix-ups at a plant that supplies the drug. U.K-based Glaxo said on Friday last that it had issued a voluntary recall of all bottles of DynaCirc remaining in the U.S market from wholesalers, pharmacies and hospitals.
As a result of the recall the drug won’t be available to patients. Alternative treatments are available to patients currently being treated with DynaCirc.
The Novartis plant in the U.S.A that manufactured the drug recently suspended operations to address problems identified by the U.S Food and Drug administration. FDA inspectors reported tablets being placed in bottles labelled for other products. This could potentially result in tablet mix-ups for products packaged at the facility. Novartis has said that production suspension is temporary and Glaxo has said that it can’t predict when the plant will resume operations or when the supply of DynaCirc will resume.
Speaking today about the product recall Liam Moloney, Healthcare Solicitor in Kildare said ‘’If you have consumed DynaCirc and have suffered an adverse reaction to this drug you should immediately attend your doctor. If your symptoms persist you may also may be entitled under the law of product liability to claim damages’’ .
